Acute Myeloid Leukemia Diagnosis and Treatment

Diagnostic Confirmation

The presence of 21% blasts in peripheral blood with severe cytopenias establishes a presumptive diagnosis of AML, as ≥20% blasts in blood or bone marrow defines acute leukemia by WHO criteria, according to the European Society for Medical Oncology 2
Urgent bone marrow aspiration and biopsy must be performed to confirm diagnosis, determine AML subtype, and obtain material for cytogenetics, flow cytometry, and molecular testing, as recommended by the National Comprehensive Cancer Network 1

Intensive induction chemotherapy is the standard approach for fit patients, typically consisting of cytarabine-based regimens, with the goal of achieving complete remission, defined as <5% bone marrow blasts, ANC >1.0 × 10⁹/L, and platelet count >100 × 10⁹/L, according to the American Society of Clinical Oncology 1
Consolidation therapy after achieving remission should include at least one cycle of high-dose cytarabine for good-risk patients, as recommended by the European Society for Medical Oncology 1, 4
Allogeneic stem cell transplantation is recommended for intermediate- and poor-risk patients with HLA-matched sibling or unrelated donor, provided age and performance status permit, according to the National Comprehensive Cancer Network 1, 4
Non-intensive therapy, including hypomethylating agents, is appropriate for unfit patients, as recommended by the American Society of Clinical Oncology 1, 4

Empiric broad-spectrum antibiotics are mandatory if fever develops with ANC <1.0 × 10⁹/L, as mortality increases significantly with delayed treatment, according to the Infectious Diseases Society of America 3
Red blood cell transfusions should be given to maintain hemoglobin >7-8 g/dL, and platelet transfusions to maintain count >10 × 10⁹/L, as recommended by the American Society of Clinical Oncology 1
Avoid excessive red cell transfusions until WBC is controlled, as this increases blood viscosity and leukostasis risk, according to the European Society for Medical Oncology 5

Response assessment after induction includes bone marrow biopsy to document remission status, as recommended by the National Comprehensive Cancer Network 1
The prognosis depends heavily on cytogenetic and molecular risk stratification from the bone marrow evaluation, with good-risk AML having significantly better outcomes than intermediate- or poor-risk disease, according to the American Society of Clinical Oncology 1, 4